Abstract
The worldwide control of tuberculosis (TB) requires affordable and easy to apply test(s), which could diagnose active/latent TB and differentiate from vaccination with Mycobacterium bovis Bacillus Calmette Guerin (BCG), and exposure to environmental mycobacteria. The currently used test for the diagnosis of TB is the in vivo administered tuberculin skin test that induces delayed-type hypersensitivity (DTH) skin responses in individuals infected with M. tuberculosis. However, this test lacks sensitivity and specificity because of the non-standardized and cross-reactive nature of the antigens used, i.e. purified protein derivative (PPD) of M. tuberculosis. Since PPD contains antigens shared between M. tuberculosis, BCG, and environmental mycobacteria, it cannot differentiate between infection with M. tuberculosis, vaccination with BCG, and exposure to environmental mycobacterial. To overcome the problems associated with PPD, there is a need to identify M. tuberculosis-specific antigens as new tuberculins for in vivo diagnostic applications in humans.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
